A universal and common pathological process of cardiovascular diseases is myointimal hyperplasia (MH), characterized by augmented proliferation and migration of vascular smooth muscle cells (VSMCs) and increased synthesis of extracellular matrix, which progressively obliterates the vessel lumen. 1 These cellular events are the result of a dedifferentiation process of VSMCs, which are capable of losing their contractile function and re-establishing a more undifferentiated synthetic genotype and phenotype. 2 This VSMC plasticity can be observed as a response to growth factors, cytokines, cell-cell contacts, lipids, and extracellular matrix components and is defined by a distinct gene expression profile. 3,4 VSMCs further exhibit hyperpolarized mitochondria and an imbalanced replication/apoptosis ratio, which makes them highly proliferative. 5 Prevention of this VSMC phenotype holds promise for alleviating MH and subsequent obliterative vascular diseases like in-stent restenosis (ISR).
These effects can be cell type-or tissue-specific. Previous studies suggest that miRNAs are critically involved in MH and ISR. 7 Modulation of various miRNAs can inhibit myointimal growth, suggesting a therapeutic approach for vascular disease. 7, 8 Most in vivo studies examining MH have used rodent models and systemic miRNA modulation carrying the risk for off-target effects. 9 To increase translational potential, we decided to use our previously described orthotopic transplant model, 5, 10 and now report a novel strategy for local anti-miR (-21) delivery engaging coatable drug-eluting stents (DES).
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

miR-21 Is Upregulated During Myointima Formation
Balloon-injured human internal mammary arteries (IMAs) were implanted into the abdominal aortic position of athymic Rowett nude (RNU) rats (humanized mammary artery [hMA] model) to study MH as reported previously. 5, 10 In a second cohort, each IMA had a single bare-metal stent (BMS) deployed before implantation. Ten days post implantation, we retrieved the IMAs from both groups (denoted hMA 10 and BMS 10 , respectively) and measured tissue expression of 8 miRNAs previously shown to be associated with the proliferative response in vascular (patho-)physiology (miR-1, -21, -29b, -133a, -143, -145, -221, and -222). 8, 11 Nondenuded native hMAs served as controls (native). Significant changes in miRNA expression were detected for all except 1 (miR-221; Figure 1A ; Figure I in the online-only Data Supplement). Except for miR-21 (significantly upregulated), all other remaining miRNAs were substantially repressed. miRNA expression levels were similar in the hMA 10 and BMS 10 groups for all miRs measured. Importantly, miR-21 expression was low in native hMA and nonstenosed human coronary arteries (hCA healthy ), while previously stented, diseased human coronary arteries (hCA stent ) had similar miR-21 levels to the hMA 10 /BMS 10 groups ( Figure 1A ), suggesting that our humanized in vivo model closely mimics human ISR. As miR-21 was substantially upregulated, it appeared distinctly suitable for anti-miR-based therapeutic modulation.
Smooth muscle cell actin-positive myointimal cells in the hMA model colocalized with human leukocyte antigen I and did not express rat major histocompatibility complex I ( Figure 1B ), confirming human myointimal origin. SMemb (embryonic smooth muscle myosin heavy chain; VSMC dedifferentiation marker) and SM heavy chain (VSMC-specific marker) were found in the myointima of hMA 28 vessels (immunofluorescence; Figure 1C ), as was miR-21 in comparison with undenuded control hMA and nonstenosed human coronary arteries when analyzed by in situ hybridization ( Figure 1D ). miR-21 was ≈4-fold upregulated in injured human arteries and abundantly expressed in the VSMC-rich human myointima.
Systemic miR-21 Repression
We sought to inhibit miR-21 in the hMA model through systemic administration. RNU rats received 1 intravenous dose of either 1 mg/kg anti-21 in the low-dose or 5 mg/kg anti-21 in the high-dose (HD) group, 1 day after hMA implantation. Vessels were retrieved after 28 days for histological evaluation ( Figure 2A ). Untreated hMA 28 arteries showed a circular, cell-rich myointima with increased extracellular matrix deposition. Myointimal area was reduced in both anti-21 treatment groups, an effect that was markedly more pronounced with HD treatment.
Confocal immunofluorescence staining revealed similar composition of the myointimas in all of the above groups ( Figure 2B ). Double immunofluorescence staining against smooth muscle cell actin and fibroblast activation protein showed high myointimal SMC content with fibroblastic cells indicating an area of active tissue remodeling. Quantification of luminal obliteration confirmed significantly more luminal preservation in the anti-21 HD group compared with both untreated controls and the anti-21 low-dose group ( Figure 2C ). Effective knockdown of miR-21 in the hMA vessels with anti-21 HD treatment was confirmed by quantitative real-time polymerase chain reaction ( Figure 2D ).
We next evaluated miR-21 off-target knockdown in other organs. As expected, we observed significant reduction of miR-21 expression in kidneys ( Figure 2E ), as well as liver, heart, and lungs ( Figure IIA in the online-only Data Supplement). Although other measured serum markers did not change significantly, creatinine elevation coincided with kidney miR-21 repression, indicating that systemic anti-21 HD administration negatively affects kidney function in our specific RNU rat model ( Figure 2F ). As the locked nucleic acid-antisense was fluorescein-tagged, we were able to demonstrate (by fluorescence imaging) heavy renal accumulation of systemically delivered anti-21 ( Figure 2G ). This potentially toxic side effect of anti-21 in kidneys should be taken into account when considering translational systemic miR-21 inhibition.
Local miR-21 Repression Using Anti-21-Eluting Stents
To minimize the above-noted off-target effects, we coated stents with anti-21 to permit local delivery to the injured hMA vessels. Successful stent coating with anti-21 was confirmed by fluorescein fluorescence and scanning electron microscopy ( Figure III in the online-only Data Supplement). The total anti-21 amount coated onto each stent was similar to the systemic HD dosage (5 mg/kg). Anti-21 stents were compared with otherwise identical BMSs in the humanized model ( Figure IIIB in the online-only Data Supplement), and ISR was assessed after 28 days. Trichrome staining revealed marked myointima formation within the BMS lumen and much reduced myointima in anti-21-stented hMA ( Figure 3A ). Fixation and cutting protocols for stented vessels necessitated stent strut removal, leaving gaps adjacent to the internal elastic lamina. Despite this, ISR was clearly decreased in the anti-21-stent group as observed by histological quantification ( Figure 3B ). Optical coherence tomographic images obtained immediately after vessel retrieval and before fixation, also indicated markedly smaller myointimal growth within the anti-21-stent 28 lumen (Movie S1 in the online-only Data Supplement; Figure 3C ). Effective anti-21 uptake in the stented vessels was confirmed by fluorescence-imaging and -intensity analysis ( Figure 3D and 3E) . Screening for off-target regulation did not reveal any miR-21 expression changes in kidney ( Figure 3F) , liver, heart, or lung ( Figure IIB in the online-only Data Supplement). Furthermore, serum creatinine was unaffected by anti-21-stent placement ( Figure 3G ) and fluorescence confirmed no accumulation of anti-21 in the kidneys ( Figure 3H ).
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Anti-21 Does Not Affect Reendothelialization
We investigated whether anti-21 treatment affects reendothelialization of balloon-injured arteries. Lewis rats underwent balloon injury of their abdominal aortas and received the above-mentioned, highly effective anti-21 HD intravenously or remained untreated as control. Interestingly, after 28 days, endothelial cell (EC)-specific RECA-1 (rat endothelial cell antigen 1) staining revealed near complete reendothelialization in both groups ( Figure 4A and 4B). We also performed organ chamber experiments to assess the functional capacity of the regenerated endothelium to regulate vasodilatation ( Figure 4C ). Both control and anti-21-treated aortas showed similar endothelial-dependent and endothelial-independent relaxation characteristics. Together, these results indicate that regrowth of functionally intact endothelium in denuded arteries occurs despite anti-21 treatment.
Of importance, in vitro proliferation of human coronary artery ECs remained unaffected by anti-21 after applying different stimuli, such as serum starvation or platelet-derived growth factor (PDGF) treatment ( Figure 4D and 4E) . Interestingly, only forced overexpression of miR-21 (pre-21 treatment) substantially increased MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide dye)-detected EC proliferation (in comparison with scr-miR and anti-21; Figure 4D and 4E), indicating a less prominent regulatory effect of miR-21 inhibition in vascular ECs, an effect that was previously reported by others as well. 7, 12 
Anti-21 Inhibits Proliferation of Smooth Muscle Cells In Vivo, Ex Vivo, and In Vitro
To confirm the observed antiproliferative effect of miR-21 repression in VSMCs ex vivo, we stimulated fresh pieces of IMA with PDGF, an important driving factor for MH 13 and miR-21 upregulation in SMCs 14 and fibroblasts. 15 PDGF not only increased miR-21 expression ( Figure 4F ) but also decreased phosphatase and tensin homolog (PTEN; Figure 4G ), a wellestablished target gene of miR-21 in vascular remodeling. 7 Simultaneous anti-21 treatment diminished PDGF-mediated PTEN suppression, confirming the intermediary and crucial role of miR-21 ( Figure 4G ). Inhibition of miR-21 abolished the proproliferative effect of PDGF (and serum starvation) on human coronary artery SMCs, whereas miR-21 overexpression substantially induced the proproliferative response ( Figure 4H and 4I) . 
Discussion
The treatment of patients with ISR remains challenging, despite recent advances in device technology and pharmacological treatment. BMSs are still widely used during percutaneous coronary interventions, despite their considerably high risk of ISR, especially when used for complex pathological lesions or difficult anatomic scenarios. 16 The use of antiproliferative DES substantially decreased myointimal proliferation and thus ISR. Several generations of DES have entered the clinic and markedly reduced the burden, particularly of early ISR. However, late ISR after DES placement remains a significant problem associated with delayed reendothelialization because of cell-unspecific effects and prolonged thrombogenicity. 17 Thus, the discovery of highly effective treatments that allow local delivery and mainly target SMC-dominant MH, while not interrupting the reendothelization process, remains appealing. The major aim of this study was to technically assess the feasibility of using miR modulation locally delivered from a DES to prevent a certain vascular response to injury, in our case ISR.
Vascular remodeling is a term widely used for adaptive structural changes of the vasculature to different types of injury. Myointima formation may develop after percutaneous coronary intervention and stenting of diseased arteries and leads to ISR. Numerous miRNAs have previously been suggested to play a role in proliferation-associated vascular diseases. Out of 8 miRNA candidates assessed in this study, all except for 1 miRNA (miR-221) were substantially altered in injured (hMA groups) as well as stented hMAs (BMS groups) compared with controls. All miRNAs but miR-21 (increased expression) were significantly reduced in response to injury.
The other miRNAs that were downregulated included the muscle cell-enriched miR-1 and miR-133, which are crucial mediators in muscular development and in response to vascular injury. 18 miR-29b, which has been identified as an important mediator of the fibrotic response in the vasculature by directly targeting several collagen isoforms as well as other important components of the extracellular matrix, such as elastin and fibrillin1. 19, 20 The miR-143/-145 cluster is particularly important in its ability to perform phenotypic switching in VSMCs in response to vascular injury. 21, 22 miR-221 and miR-222 have been shown to be prominently involved in vascular proliferation by targeting p27 (Kip1) and p57 (Kip2), as well as the stem cell factor c-Kit in VSMCs. 23 Of importance for treatment considerations, miR-21 was the only miRNA in our study that was significantly upregulated in response to injury. miRNAs with augmented expression in response to injury and disease are amenable for antisense oligonucleotide (anti-miR) inhibition and may therefore present promising therapeutic targets on the molecular level. Therapeutic overexpression of suppressed miRs is currently less attractive, and the delivery of miRNA-mimics Animals in the treatment group received 5 mg/kg anti-21 intravenously 1 day post denudation. After 28 days, vessels were recovered and stained for endothelial cells. B, There were no relevant differences in endothelial coverage between control 28 and anti-21 28 (mean±SD, n=5 per group, unpaired t test). C, Endothelial function was assessed in organ chamber experiments (mean±SEM, n=6 [control 28 ], n=6 [anti-21 HD 28 ], n=3 [control 3 ]). All 3 groups showed similar endothelial-independent relaxation characteristics, when stimulated with nitroglycerine. In contrast, stimulation with acetylcholine had no effect 3 days after vessel injury, whereas both control 28 or pre-miRNAs for miRNA induction remains problematic. Although locked nucleic acid-based miRNA-mimics are becoming available in the near future, traditional delivery has involved lentiviral or adenoviral approaches, presenting risks common to gene therapy. 24 Some newer studies from the cancer field have explored packaging synthetic miRNA duplexes within lipid nanoparticles and have been successful with this approach in murine models. 25 A major difference between the classical pharmacological approach and the novel field of miRNA-based therapeutics is that the latter may regulate entire gene or protein networks. 8 Recent animal and human efficacy data are promising, suggesting that anti-miRs have the potential to become a new class of drugs. 26, 27 Anti-miRs have several advantages for drug development, including their small molecular size and the frequent conservation of their target miRNAs across species. 6 miR-21 is considered to be among the most readily inducible vascular miRNAs, associated with increased cell proliferation and decreased apoptosis in the vessel wall. 12, 28 In a previous study, antisense-mediated inhibition of miR-21 using pluronic gel reduced myointima in balloon-injured rat carotid arteries. 7 The authors showed that PTEN and Bcl-2 upregulation were involved in the anti-miR-21-mediated cellular effects. 7 Similarly, in vein graft failure studies, miR-21 was significantly upregulated following engraftment in mouse, pig, and human models. Genetic deletion of miR-21 in mice and grafted veins limited the proliferative response and reduced myointima formation. 29 Our anti-21-eluting stent was highly effective in reducing VSMC proliferation and alleviating MH and ISR. Importantly, we observe neither miR-21 suppression in other organs nor off-target side effects with this approach. Anti-21, in contrast to the currently used DES medications, such as rapamycin, 30 did not delay vessel reendothelization, a side effect thought to be the major cause of stent thrombosis and late ISR. 16 In our study, systemic anti-21 allowed recoverage of balloon-injured rat aortas with functionally intact endothelium. In addition, anti-21 treatment did not inhibit EC proliferation in vitro. This anti-21 effect is most likely because of the low concentration of miR-21 in the endothelium compared with its expression levels in VSMC, being particularly enriched in the myointima and vessel media in response to injury and stent deployment. 12 Off-target effects in organs in which miRNA modulators assimilate to a much higher extent than the targeted vasculature are a much-debated compromise of antisense oligonucleotide therapeutics. Anti-miR-21 treatment in our ISR studies increased creatinine levels in RNU rats, which might be because of the immune-incompetent state of the rats, and thus model specific. Of note, previous studies evaluating the development of kidney fibrosis in mice showed protective effects of miR-21 inhibition. 31, 32 Of importance, these studies were mainly conducted in diseased mice to prevent or reverse kidney fibrosis, and thus were not performed in undiseased and otherwise healthy rodents. miR-21 plays an important role in controlling cell apoptosis in various cells types (such as tubular epithelial cells). Inhibition of miR-21 in tubular epithelial cell increases cell death, [33] [34] [35] which could be an explanation of our observation in the RNU rats.
We think this proof-of-concept and technical assessment study for the efficacy and safety of anti-21-eluting stents demonstrate the feasibility of local delivery for miRNAbased therapeutics being applicable for vascular diseases. The method could potentially be optimized by modulating the release kinetics and dosing of the anti-miR or by potentially combining multiple anti-miRs on a single stent. Future trials should address these issues, as well as its long-term efficacy, in preventing the occurrence of late ISR.
